Share

June 2015; 2 (3) ArticleOpen Access

Clinical course and treatment of anti-HMGCR antibody–associated necrotizing autoimmune myopathy

Sudarshini Ramanathan, Daman Langguth, Todd A. Hardy, Nidhi Garg, Chris Bundell, Arada Rojana-Udomsart, Russell C. Dale, Thomas Robertson, Andrew L. Mammen, Stephen W. Reddel
First published April 2, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000096
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
4802

Share

Article Information

vol. 2 no. 3 e96
DOI: 
https://doi.org/10.1212/NXI.0000000000000096
PubMed: 
25866831
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 24, 2014
  • Accepted in final form January 20, 2015
  • First Published April 2, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Sudarshini Ramanathan, FRACP,
    2. Daman Langguth, FRACP, FRCPA,
    3. Todd A. Hardy, FRACP, PhD,
    4. Nidhi Garg, MBBS,
    5. Chris Bundell, PhD,
    6. Arada Rojana-Udomsart, PhD,
    7. Russell C. Dale, PhD,
    8. Thomas Robertson, FRCPA,
    9. Andrew L. Mammen, MD, PhD and
    10. Stephen W. Reddel, FRACP, PhD
  1. Sudarshini Ramanathan, FRACP,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Sudarshini Ramanathan has received a scholarship from the National Health and Medical Research Council (Australia)

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Daman Langguth, FRACP, FRCPA,
    3. Scientific Advisory Boards:

    1. Tocilizumab in asthma phase 1 trial, university of Queensland, not for profit.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speakers fees for Roche on off label use of rituximab

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Sullivan Nicolaides Pathology, director of immunology, 8 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NHMRC development grant for Grass allergy research (Pas n 1 sIgE test)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Todd A. Hardy, FRACP, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Advances in Clinical Neuroscience, Associate Editor, 2013-2014

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Nidhi Garg, MBBS,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Current position as Neuromuscular Fellow at Concord Hospital is partly funded by the drug company, Allergan.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Chris Bundell, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Arada Rojana-Udomsart, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Russell C. Dale, PhD,
    8. Scientific Advisory Boards:

    1. Queensland Children's Medical Institute Research advisory committee. Not for profit.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. received an honoraria for lecturing from Biogen Idec

    Editorial Boards:

    1. Editorial advisory board member of MSARD Editorial board member of Neurology: Neuroimmunology and Neuroinflammation Editorial board member of European Journal of Paediatric Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. Biogen Idec 1000 dollar honoria in 2008

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NHMRC national grant in 2011 national grant for encephalitis study NHMRC practitioner fellowship 2014-8 NHMRC project grant 2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Thomas Robertson, FRCPA,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Andrew L. Mammen, MD, PhD and
    10. Scientific Advisory Boards:

    1. aTYR pharmaceuticals advisory board Biogen advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Experimental Neurology, Editorial Board, 2013-Arthritis and Rheumatism, Editorial Board, 2014-

    Patents:

    1. Patented test for anti-HMGCR antibodies that is licensed to INOVA diagnostics

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, K08

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. Licensed test for anti-HMGCR antibodies to INOVA Diagnostics

    Royalty Payments, Technology or Inventions:

    1. Licensed test for anti-HMGCR antibodies to INOVA Diagnostics

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Stephen W. Reddel, FRACP, PhD
    11. Scientific Advisory Boards:

    1. 1. CSL 2. Baxter 3. Genzyme 4. Biogen 5. National Immunoglobulin Governmental Advisory Council, Australia

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1. CSL 2. Genzyme 3. Biogen

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NSW Health, Australia

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Beeren Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. 1. Sydney Neurology 2. Medical Safety Systems

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (S.R., T.A.H., N.G., S.W.R.), Concord Repatriation General Hospital, Sydney, New South Wales, Australia; Neuroimmunology Group (S.R., R.C.D.), Institute for Neuroscience and Muscle Research, The Kids Research Institute at the Children's Hospital at Westmead, Sydney Medical School, University of Sydney, New South Wales, Australia; Department of Neurology (S.R.), Westmead Hospital, Sydney, New South Wales, Australia; Sullivan Nicolaides Pathology (D.L.), Brisbane, Queensland, Australia; Concord Clinical School (T.A.H., S.W.R.), University of Sydney, New South Wales, Australia; Clinical Immunology (C.B.), PathWest, QEII Medical Center, Nedlands, Western Australia, Australia; School of Pathology and Laboratory Medicine (C.B.), University of Western Australia, Nedlands, Western Australia, Australia; Australian Neuro-Muscular Research Institute (ANRI) and Centre for Neuromuscular and Neurological Disorders (CNND) (A.R.-U.), University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia; Pathology Queensland (T.R.), Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia; and National Institute of Arthritis and Musculoskeletal and Skin Diseases (A.L.M.), National Institutes of Health, Bethesda, MD.
  1. Correspondence to Dr. Reddel: swreddel{at}sydneyneurology.com.au

Article usage

Article usage: April 2015 to November 2023

AbstractFullPdfSource
Apr 20153384752Highwire
Apr 2015010260pmc
May 20151523437Highwire
May 20150143112pmc
Jun 201541819296Highwire
Jun 2015012972pmc
Jul 20158210120Highwire
Jul 201507741pmc
Aug 20151157432Highwire
Aug 2015010553pmc
Sep 20158611420Highwire
Sep 2015013751pmc
Oct 2015618427Highwire
Oct 2015011748pmc
Nov 2015808127Highwire
Nov 2015012058pmc
Dec 2015647610Highwire
Dec 2015012152pmc
Jan 2016579418Highwire
Jan 2016012738pmc
Feb 20166310926Highwire
Feb 2016011242pmc
Mar 20166315429Highwire
Mar 2016012573pmc
Apr 20166112121Highwire
Apr 2016010772pmc
May 20168712015Highwire
May 2016010490pmc
Jun 20166512021Highwire
Jun 2016010655pmc
Jul 20165410413Highwire
Jul 2016015741pmc
Aug 2016458018Highwire
Aug 2016016749pmc
Sep 20163223410Highwire
Sep 2016017734pmc
Oct 20167410832Highwire
Oct 2016023039pmc
Nov 2016569324Highwire
Nov 2016015239pmc
Dec 20161698920Highwire
Dec 2016011530pmc
Jan 2017129546Highwire
Jan 2017011640pmc
Feb 2017497416Highwire
Feb 2017012042pmc
Mar 2017498818Highwire
Mar 2017014053pmc
Apr 2017435210Highwire
Apr 20172989100pmc
May 2017245311Highwire
May 201725121143pmc
Jun 2017212345Highwire
Jun 20171890102pmc
Jul 20175121614Highwire
Jul 20172393113pmc
Aug 20174724022Highwire
Aug 20173496115pmc
Sep 20173013412Highwire
Sep 2017187886pmc
Oct 20174413611Highwire
Oct 201726116140pmc
Nov 2017267312Highwire
Nov 201735115157pmc
Dec 2017195712Highwire
Jan 2018185318Highwire
Feb 2018266626Highwire
Mar 2018195616Highwire
Apr 2018176313Highwire
Apr 201814115131pmc
May 20181912310Highwire
Jun 2018151168Highwire
Jun 20181994119pmc
Jul 20181510013Highwire
Aug 2018178912Highwire
Aug 20181494117pmc
Sep 2018207822Highwire
Oct 201813607Highwire
Nov 201816935Highwire
Dec 201813718Highwire
Jan 2019244317Highwire
Feb 2019233413Highwire
Mar 2019374930Highwire
Apr 2019293045Highwire
May 2019293825Highwire
Jun 2019264223Highwire
Jul 2019347629Highwire
Aug 2019224128Highwire
Sep 2019172617Highwire
Oct 2019342812Highwire
Nov 2019293429Highwire
Dec 2019192121Highwire
Jan 2020272625Highwire
Feb 2020223320Highwire
Mar 2020192524Highwire
Apr 2020152020Highwire
May 202082828Highwire
Jun 202072625Highwire
Jul 2020112621Highwire
Aug 202081420Highwire
Sep 2020104024Highwire
Oct 2020135121Highwire
Nov 2020154334Highwire
Dec 2020103119Highwire
Jan 2021202124Highwire
Feb 2021123021Highwire
Mar 2021143924Highwire
Apr 2021152410Highwire
May 202182914Highwire
Jun 2021132719Highwire
Jul 2021134221Highwire
Aug 2021135823Highwire
Sep 2021146525Highwire
Oct 2021135934Highwire
Nov 2021185630Highwire
Dec 202165021Highwire
Jan 202285624Highwire
Feb 2022146420Highwire
Mar 2022179119Highwire
Apr 202285916Highwire
May 2022116626Highwire
Jun 202288821Highwire
Jul 2022189715Highwire
Aug 20222711323Highwire
Sep 20221512524Highwire
Oct 20221213530Highwire
Nov 20222015137Highwire
Dec 202248621Highwire
Jan 20231512319Highwire
Feb 20231211315Highwire
Mar 20231711323Highwire
Apr 20231511720Highwire
May 20231416632Highwire
Jun 2023311717Highwire
Jul 2023813926Highwire
Aug 2023514518Highwire
Sep 2023913713Highwire
Oct 20231111313Highwire
Nov 202387012Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Alert Me

Recommended articles